Study on Proton Pump Inhibitors and Tumor Risks
Author Information
Author(s): Zhang Ya-Jun, Duan Dan-Dan, Tian Qian-Yu, Wang Cai-E, Wei Shu-Xun
Primary Institution: The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Hypothesis
This study aims to comprehensively analyze the relationship between proton pump inhibitors (PPIs) and tumor adverse events (TAEs).
Conclusion
TAEs constitute a small but significant fraction of PPI-related adverse events, highlighting the need for cautious long-term use of PPIs.
Supporting Evidence
- 3,133 tumor adverse events were identified, representing 2.36% of all PPI-related adverse events.
- The most common TAEs were gastric cancer (19.05%) and malignant neoplasm (7.23%).
- Disproportionality analysis revealed ten significant TAEs associated with PPIs.
- TAEs were less likely to occur in elderly patients, with odds ratios indicating lower risk.
- 29.70% of TAEs resulted in a fatality.
Takeaway
Proton pump inhibitors, which help with stomach problems, might cause tumors if used for a long time, so doctors need to be careful when prescribing them.
Methodology
The study analyzed PPI adverse reaction reports from the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2024, focusing on disproportionality analysis using Reporting Odds Ratio (ROR).
Potential Biases
Potential underreporting of adverse events in elderly patients and lack of data on confounding factors.
Limitations
The majority of data originates from the United States, and the database does not provide information on other risk factors such as diet or smoking.
Participant Demographics
Median age of participants reporting TAEs was 59 years, with a majority being male.
Statistical Information
P-Value
p<0.001
Confidence Interval
[0.87, 0.95]
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website